Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.
This trial is active, not recruiting.
|Conditions||retinal detachment, vitreoretinopathy proliferative|
|Start date||June 2013|
|End date||November 2014|
|Trial size||20 participants|
|Trial identifier||NCT01860586, HsuPVR13, MARPVR2013|
The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
The effect of intravitreal bevacizumab injections on retinal detachment rate (increase or decrease)
time frame: up to 6 months
The effect of intravitreal bevacizumab injections on the development of recurrent Proliferative vitreoretinopathy (PVR).
time frame: 6 months
Male or female participants at least 18 years old.
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD due to PVR with planned silicone oil instillation.
- Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery.
- Traction retinal detachment due to proliferative diabetic retinopathy.
- Inability to flatten retina completely intraoperatively
- Known allergy or contraindication to intravitreal bevacizumab
|Official title||A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy|
|Principal investigator||Jason Hsu, MD|
Call for more information